Trem2-APOE Pathway in Alzheimer's Disease: Exploring the differential effects of R47H on the APOE3 and APOE4 backgrounds in a tauopathy model

阿尔茨海默病中的 Trem2-APOE 通路：探索 R47H 对 tau 蛋白病模型中 APOE3 和 APOE4 背景的不同影响

• 批准号: 10536429
• 负责人: Gillian Kirova Carling
• 金额: $ 4.68万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-18 至 2025-08-17
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10536429
• 关键词: AKT inhibition; Affect; Affinity; Age; Alleles; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease risk; Amyloid beta-Protein; Automobile Driving; Biomass; Clinical; Cognitive; Data; Dementia; Development; Disease; Genetic Risk; Genotype; Health; Impairment; In Vitro; Inflammation; Inflammatory; Inflammatory Response; Ligands; Light; Link; Lipoproteins; Measures; Memory impairment; Metabolic; Metabolism; Microglia; Mitochondria; Modeling; Mus; Mutation; Nerve Degeneration; Neurofibrillary Tangles; Onset of illness; Pathogenesis; Pathogenicity; Pathology; Pathway interactions; Persons; Phenotype; Phosphotransferases; Play; Population; Production; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Research; Respiration; Risk Factors; Role; Senile Plaques; Signal Transduction; Synaptophysin; TREM2 gene; Tauopathies; Therapeutic Effect; Toxic effect; Variant; disorder risk; experimental study; functional outcomes; genetic risk factor; human old age (65+); improved; in vivo; metabolomics; mitochondrial dysfunction; mouse model; neuroinflammation; new therapeutic target; novel; receptor; response; risk variant; tau Proteins; transcriptomics

Project Summary Alzheimer’s disease (AD) is one of the most common forms of dementia, affecting one in ten people over the age of 65 and nearly half of people over the age of 85. AD is currently untreatable, posing a significant health concern. Many attempted treatments for AD target amyloid-beta (Ab) plaques, but these treatments have all failed in clinical trials1,2. Emerging evidence shows that tau pathology may play a causal role in the development of AD. Inflammation prompted by microglia may precede the spread of pathogenic tau3-6, and most AD risk genes are found in microglia, supporting a significant role for inflammation in disease7,8. Inflammation requires metabolic reprogramming to provide the energy and substrates needed for activation9,10, and mitochondrial dysfunction could contribute to aberrant inflammatory responses in AD11. The APOE4 risk allele along with the R47H variant of the microglial Trem2 receptor both display large effect sizes in increasing AD risk. APOE4 is found in approximately 20% of the population, whereas the R47H mutation is much rarer, representing less than 1% of the population12. The APOE3 allele is considered neutral to disease risk and is often used as a control comparison in experiments. APOE is a known ligand of the Trem2 receptor, and Trem2 activation robustly increases microglial APOE expression, as well as affecting cellular metabolism and inflammation. Activation of the microglial Trem2-APOE pathway is associated with heightened inflammation13,14. However, the mechanistic underpinnings of the pathway are not well understood, and there has been little research on the interactions between risk variants R47H and APOE4. My preliminary data indicates that R47H/+ has a remarkable differential effect on the APOE3 background compared to the APOE4 background, such that R47H with APOE3 (R47H-E3) has heightened inflammation in response to tau and increased mitochondrial respiration, but R47H with APOE4 (R47H-E4) has low inflammatory response and decreased mitochondrial function. This differential response is accompanied by enhanced AKT activation in R47H-E3 but reduced AKT activation in R47H-E4, suggesting potential mechanistic involvement in these phenotypes. I hypothesize that alterations in AKT signaling drive the differential effects of R47H on mitochondrial respiration and inflammation in the E3 vs. E4 background. In this proposal, I aim to further elucidate the interactions of R47H with different APOE genotypes to affect microglial metabolism and inflammation, both in vitro using a primary microglia model and in vivo using a tauopathy mouse model. I will then explore the potential mechanistic involvement of AKT in this pathway using AKT inhibition. These studies will provide a better understanding of the function and mechanisms of the disease-implicated Trem2-APOE pathway in microglia, providing novel targets for the treatment of AD.

项目总结